查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884055

人类抗凝血酶市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032）

Human Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 请询问到货日

价格

人类抗凝血酶市场成长驱动因子

由于临床意识的提高、罕见凝血障碍盛行率的增加以及在外科手术和重症监护领域应用范围的扩大，全球人类抗凝血酶市场正经历稳步增长。根据最新的产业分析，预计该市场在2024年的价值将达到3.671亿美元，到2025年将达到3.813亿美元。预计2032年将进一步成长至5.12亿美元，预测期内复合年增长率（CAGR）为4.3%。 2024年，欧洲以43.28%的市占率占主导地位。这主要归功于欧洲成熟企业的强大实力、完善的医疗保健基础设施以及血浆来源抗凝血酶产品的广泛供应。

人类抗凝血酶是一种源自人类血浆的糖蛋白，在灭活凝血酶和其他丝氨酸蛋白酶以及预防异常血液凝固方面发挥关键作用。抗凝血酶浓缩物在外科手术、心臟手术、器官移植和体外膜氧合（ECMO）治疗的应用日益广泛，推动了市场成长。此外，遗传性抗凝血酶缺乏症、瀰漫性血管内凝血（DIC）和血栓形成的日益普遍，也进一步推动了全球对抗凝血酶替代疗法的需求。

主要市场参与者包括 CSL、Octapharma AG、Grifols S.A.、Kedrion S.p.A. 和武田药品工业株式会社。所有这些公司都受益于其强大的区域影响力以及在血浆分离产品领域成熟的产品组合。这些公司持续的创新和策略扩张将继续支持市场成长。

市场驱动因素与机会

人类抗凝血酶市场的主要驱动因素是其在治疗应用上日益广泛的应用。遗传性抗凝血酶缺乏症影响全球约 0.02% 至 0.05% 的人口，这意味着成千上万的患者需要终身接受替代治疗。抗凝血酶浓缩物在心臟手术患者的管理中尤其重要。例如，2024 年 6 月 "胸腔外科年鑑" 简报报导，美国每年平均每 10 万人口进行 271.5 例心臟手术，凸显了临床对抗凝血酶治疗的依赖性。

此外，与肝素合併治疗可产生协同抗凝血效果，为市场成长带来新的潜力。此类联合疗法正越来越多地被纳入临床方案，以改善肝素抗性和复杂凝血障碍患者的治疗效果。

市场限制因素与挑战

儘管具有重要的临床意义，但由于血浆来源抗凝血酶的安全性问题，包括过敏反应、出血风险以及潜在的感染风险，市场仍面临许多限制。高剂量，尤其是在严重败血症或与肝素合併使用时，会增加出血风险，从而限制了其在某些患者群体中的应用。

此外，复杂的监管框架和不一致的报销政策，尤其是在中低收入国家，也构成了市场挑战。冗长的审批流程、严格的安全法规以及有限的保险覆盖范围延缓了新产品的广泛应用和商业化。

市场趋势

近期趋势表明，抗凝血酶製剂的应用范围正在扩大，不再局限于遗传性凝血功能障碍。在日本，抗凝血酶已被纳入脓毒症合併弥散性血管内凝血（DIC）患者的标准治疗方案，获批剂量高达每日1500国际单位（IU），这充分体现了此类产品的治疗多样性。此外，外科手术中对抗凝剂的临床需求持续推动终端使用者（主要是医院和诊所）的采用。同时，製药和生技产业也在拓展其在研究和诊断领域的应用。

区隔市场分析

  • 依应用领域划分：截至2024年，由于其在外科手术和肝素抗性患者中的广泛应用，治疗性应用占了最大的市场占有率。研究和诊断性应用也在成长，但成长较慢。
  • 依剂型划分：冷冻干燥粉末因其稳定性佳、易于操作而占主导地位，广泛应用于Thrombotrol VF（CSL）和THROMBATE III（Grifors）等产品。液体製剂的市占率微乎其微。
  • 依最终使用者划分：医院和诊所是最大的最终使用者群体，因为在治疗过程中需要直接使用抗凝血酶。

依地区划分的预测

  • 欧洲：是最大的地区，预计2024年市场规模将达到1.589亿美元。这得归功于强大的血浆分离中心网络以及法国2030等政府举措，这些举措旨在促进国内生物製药生产。
  • 亚太地区：由于人们对先天性抗凝血酶缺乏症的认识不断提高以及血浆生产基础设施的不断完善，亚太地区是成长最快的地区。
  • 北美：对血浆衍生产品的严格监管限制了其市场占有率。
  • 世界其他地区：包括拉丁美洲、中东和非洲。产品普及率低和基础设施限制导致其普及速度较慢。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家主要心血管疾病盛行率
  • 主要国家监管状况
  • 主要产业趋势（併购、合作、核准、上市等）

第五章：全球人类抗凝血酶市场分析、洞察与预测 （2019-2032）

  • 依应用领域划分的市场分析、洞察与预测
    • 治疗用途
    • 研究与诊断
  • 依剂型划分的市场分析、洞察与预测
    • 冻干粉
    • 液体
  • 依最终用户划分的市场分析、洞察和预测
    • 医院和诊所
    • 製药和生物技术
    • 研究机构
  • 依地区划分的市场分析、洞察与预测
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章：北美人抗凝血酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲人类抗凝血酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区人类抗凝血酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 南非韩国 东南亚 亚太其他地区

第九章：世界其他地区人类抗凝血酶市场分析、洞察与预测（2019-2032）

第十章：竞争分析

  • 全球市场占有率分析(2024年)
  • 企业简介
    • CSL
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Grifols, S.A.
    • Medix Biochemica
    • Kedrion S.p.A.
    • Scripps Laboratories
Product Code: FBI113611

Growth Factors of human antithrombin Market

The global human antithrombin market is witnessing steady growth due to rising clinical awareness, increasing prevalence of rare coagulation disorders, and expanding applications in surgical and intensive care settings. According to the latest industry insights, the market was valued at USD 367.1 million in 2024, is projected to reach USD 381.3 million in 2025, and is expected to grow to USD 512.0 million by 2032, reflecting a CAGR of 4.3% during the forecast period. In 2024, Europe dominated the market with a 43.28% share, attributed to the strong presence of established players, well-developed healthcare infrastructure, and wide availability of plasma-derived antithrombin products.

Human antithrombin, a glycoprotein derived from human plasma, plays a crucial role in inactivating thrombin and other serine proteases, preventing abnormal blood clotting. The growing adoption of antithrombin concentrates in surgical procedures, cardiac surgeries, organ transplants, and Extracorporeal Membrane Oxygenation (ECMO) treatments drives market expansion. Additionally, increasing prevalence of hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and thrombophilia further fuels global demand for antithrombin supplementation.

Major market players include CSL, Octapharma AG, Grifols S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited, all of which benefit from strong regional presence and established product portfolios in plasma fractionated products. Their ongoing innovations and strategic expansions continue to support the market growth.

Market Drivers and Opportunities

The primary driver of the human antithrombin market is increasing usage in therapeutic applications. Hereditary antithrombin deficiency affects roughly 0.02% to 0.05% of the global population, translating to thousands of patients requiring lifelong supplementation. Antithrombin concentrates are especially critical in managing patients undergoing cardiac surgeries. For instance, in June 2024, the Annals of Thoracic Surgery Short Reports highlighted that the annual average cardiac surgery volume in the U.S. was 271.5 per 100,000 population, emphasizing the clinical reliance on antithrombin therapies.

Moreover, combination therapies with heparin provide synergistic anticoagulant effects, presenting new avenues for market growth. Such therapies are increasingly incorporated in clinical protocols to enhance therapeutic outcomes in patients with heparin resistance or complex coagulopathies.

Market Restraints and Challenges

Despite its clinical importance, the market faces constraints due to plasma-derived antithrombin safety concerns, including allergic reactions, hemorrhage risk, and potential exposure to infectious agents. High doses, particularly during severe sepsis or when co-administered with heparin, may increase bleeding risks, limiting adoption in certain patient populations.

Additionally, the market is challenged by complex regulatory frameworks and inconsistent reimbursement scenarios, particularly in low- and middle-income countries. Lengthy approval processes, strict safety regulations, and limited insurance coverage hinder widespread adoption and slow commercialization of new products.

Market Trends

Recent trends indicate the expansion of antithrombin applications beyond hereditary deficiencies. In Japan, antithrombin is part of standard care for septic patients with DIC, with approved doses reaching 1,500 IU/day, demonstrating the therapeutic versatility of these products. Moreover, hospitals and clinics continue to lead end-user adoption due to the clinical demand for anticoagulants during surgical procedures, while pharmaceutical and biotechnology industries are increasing research and diagnostic applications.

Segmentation Analysis

  • By Application: The therapeutic segment held the largest market share in 2024 due to widespread use in surgeries and heparin-resistant patients. Research and diagnostic applications are growing but at a slower pace.
  • By Dosage Form: Lyophilized powders dominate owing to enhanced stability and ease of handling, used in products such as Thrombotrol VF (CSL) and THROMBATE III (Grifols). Liquid formulations account for minimal market share.
  • By End User: Hospitals and clinics represent the largest end-user segment due to the direct administration of antithrombin in therapeutic procedures.

Regional Outlook

  • Europe: Leading region with USD 158.9 million in 2024, supported by a strong network of plasma fractionation centers and government initiatives like France 2030, which promote local biologics production.
  • Asia Pacific: Fastest-growing region due to rising congenital antithrombin deficiency awareness and expanding plasma production infrastructure.
  • North America: Limited share due to stringent regulatory hurdles for plasma-derived products.
  • Rest of the World: Includes Latin America and Middle East & Africa, with slower adoption owing to limited product penetration and infrastructure constraints.

Competitive Landscape

The market is semi-consolidated, with CSL, Grifols S.A., Kedrion S.p.A., and Octapharma AG dominating. These companies leverage extensive product portfolios, manufacturing capabilities, and strategic collaborations to maintain leadership. Other global participants include Takeda Pharmaceutical Company Limited and Medix Biochemica, focusing on expanding antithrombin applications and research collaborations.

Conclusion

With a market value of USD 367.1 million in 2024, rising to USD 381.3 million in 2025, and projected to reach USD 512.0 million by 2032, the global human antithrombin market is poised for steady growth. Key drivers include therapeutic demand in surgeries, combination therapies, and rising awareness of coagulation disorders, while challenges such as safety concerns and regulatory barriers persist. Ongoing research, expansion in Asia Pacific, and innovative product launches are expected to shape the market trajectory through 2032.

Segmentation By Application

  • Therapeutic
  • Research & Diagnostic

By Dosage Form

  • Lyophilized Powder
  • Liquid

By End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region

  • North America (By Application, Dosage Form, End User, and Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
  • 4.2. Regolatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research & Diagnostic
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Lyophilized Powder
    • 5.2.2. Liquid
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research & Diagnostic
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Lyophilized Powder
    • 6.2.2. Liquid
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research & Diagnostic
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Lyophilized Powder
    • 7.2.2. Liquid
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. UK
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research & Diagnostic
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Lyophilized Powder
    • 8.2.2. Liquid
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Southeast Asia
    • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research & Diagnostic
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Lyophilized Powder
    • 9.2.2. Liquid
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. CSL
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. Financials (Based on Availability)
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. SWOT,Etc.
    • 10.2.2. Octapharma AG
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. Financials (Based on Availability)
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. SWOT,Etc.
    • 10.2.3. Takeda Pharmaceutical Company Limited
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. Financials (Based on Availability)
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. SWOT,Etc.
    • 10.2.4. Grifols, S.A.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. Financials (Based on Availability)
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. SWOT,Etc.
    • 10.2.5. Medix Biochemica
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. Financials (Based on Availability)
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. SWOT,Etc.
    • 10.2.6. Kedrion S.p.A.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. Financials (Based on Availability)
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. SWOT,Etc.
    • 10.2.7. Scripps Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. Financials (Based on Availability)
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 2: Global Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 3: Global Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 4: Global Human Antithrombin Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 5: North America Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 6: North America Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 7: North America Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 8: North America Human Antithrombin Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 9: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 10: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 11: Europe Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Europe Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 14: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 15: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 16: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 18: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 19: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032

List of Figures

  • Figure 1: Global Human Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Human Antithrombin Market Value Share (%), by Application, 2024 & 2032
  • Figure 3: Global Human Antithrombin Market Value Share (%), by Dosage Form, 2024 & 2032
  • Figure 4: Global Human Antithrombin Market Value Share (%), by End User, 2024 & 2032
  • Figure 5: Global Human Antithrombin Market Value (USD million), by Region, 2024 & 2032
  • Figure 6: North America Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 7: North America Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 8: North America Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 9: North America Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 10: North America Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 11: North America Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 12: North America Human Antithrombin Market Value (USD million), By Country, 2024 & 2032
  • Figure 13: North America Human Antithrombin Market Value Share (%), By Country, 2024
  • Figure 14: Europe Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 15: Europe Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 16: Europe Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 17: Europe Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 18: Europe Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Europe Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 21: Europe Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Europe Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Asia Pacific Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 24: Asia Pacific Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 25: Asia Pacific Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 26: Asia Pacific Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 27: Asia Pacific Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 28: Asia Pacific Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 29: Asia Pacific Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 30: Asia Pacific Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 31: Rest of the World Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 32: Rest of the World Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 33: Rest of the World Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 34: Rest of the World Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 35: Rest of the World Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 36: Rest of the World Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 37: Global Human Antithrombin Market Share (%), By Company, 2024